A Randomized, Single-Blind, Placebo Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK1440115 After a Single Dose and 7 Days of Repeat Dosing in Healthy Volunteers.
Latest Information Update: 08 Nov 2021
At a glance
- Drugs GSK 1440115 (Primary)
- Indications Asthma
- Focus Adverse reactions; Pharmacokinetics
- 28 Jan 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Dec 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 24 Sep 2010 New trial record